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Rennes. This strain, characterized 
by PFGE pattern 44-A1, represented 
22/25 tetracycline resistant GAS iso-
lates and 30% of the 72 GAS isolates 
identiﬁ  ed at the hospital in Pontchail-
lou in 2009. Locally, emergence of 
the 44-A1 clone led to the dramatic 
increase of GAS tetracycline resis-
tance, from 17% in 2008 to 35% in 
2009.  emm44 GAS strains, which 
share identical 5′emm sequences with 
previously designated M/ emm61 
strains (5), have mainly been isolated 
in Asia from throat and skin speci-
mens (6,7). They were rarely reported 
as responsible for invasive infections 
in France or other parts of the world 
(5,8). Polyclonal and emm25 and 
emm83 monoclonal GAS outbreaks 
have been recently described among 
drug users in Switzerland, the United 
Kingdom, and Spain (9,10) without 
robust evidence of enhanced viru-
lence of the causative GAS strains. 
In the outbreak we report, skin infec-
tions might be a leading cause of bac-
terial transmission between people 
living in poor hygienic conditions 
and overcrowded spaces. 
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Surface Layer 
Protein A Variant of 
Clostridium difﬁ  cile 
PCR-Ribotype 027
To the Editor: Rates and severity 
of Clostridium difﬁ  cile infection (CDI) 
have recently increased worldwide 
and correlate with dissemination of 
hypervirulent epidemic strains desig-
nated PCR-ribotype 027. CDI caused 
by this PCR-ribotype is characterized 
by strong toxin A and B production, 
presence of binary toxin genes, and, 
usually, a high level of resistance to 
ﬂ  uoroquinolones (1).
The mechanisms by which C. dif-
ﬁ  cile colonizes the gut during infection 
are poorly understood. In addition to 
the toxins, surface protein components 
are undoubtedly involved. In particu-
lar, the surface layer (S-layer) medi-
ates adhesion to enteric cells (2), but 
other functions have been proposed 
for this S-layer structure: it may act 
as a molecular sieve, protect against 
parasitic attack, or be a mechanism 
to evade the host immune system (3). 
Furthermore, the C. difﬁ  cile S-layer is 
the predominant surface antigen and is 
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among the main potential candidates 
for multicomponent vaccines against 
CDI (4,5). Composed of 2 major com-
ponents, the C. difﬁ  cile S-layer has 
high and low molecular weight pro-
teins (HMW and LMW, respectively), 
which are formed from the posttrans-
lational cleavage of a single precursor, 
surface layer protein A (slpA) (6). Dif-
ferent variants of the slpA gene have 
been identiﬁ  ed in C. difﬁ  cile (7).
The complete genome sequenc-
es of 2 C. difﬁ  cile PCR-ribotype 
027 strains (CD196, a nonepidemic 
strain isolated in France in 1985, and 
R20291, isolated from an outbreak 
in Stoke Mandeville, UK, in 2006) 
have been recently deposited in Gen-
Bank (accession nos. FN538970 and 
FN545816, respectively) (8). We ana-
lyzed the slpA gene of these strains 
by using the National Center for 
Biotechnology Information BLAST 
server (www.ncbi.nlm.nih.gov/blast) 
and the European Bioinformatics In-
stitute ClustalW server (www.ebi.
ac.uk/clustalw). Both strains showed 
a new and identical slpA nucleotide 
sequence. To determine if the new 
variant was conserved among PCR-ri-
botype 027 strains, we characterized 8 
additional epidemic strains belonging 
to this PCR-ribotype that were isolat-
ed in different geographic regions and 
years and showed different patterns of 
resistance to erythromycin and moxi-
ﬂ   oxacin. Three strains, AI13, AII6, 
and AIII8, were isolated in 3 hospitals 
in Belgium during a European pro-
spective study conducted in 2005 (9). 
C. difﬁ  cile DI12 was isolated in Ire-
land during the same study. C. difﬁ  cile 
GII7 and LUMC46 were isolated in 
the Netherlands in 2005 and 2008, re-
spectively. C. difﬁ  cile M43 and A422 
were isolated in Calgary (Canada) in 
2001 from 2 outbreaks.
Six strains were resistant to eryth-
romycin (MICs >256 mg/L) and mox-
iﬂ  oxacin (MICs 12–256 mg/L). AIII8 
was resistant to erythromycin (MIC 
>256 mg/L) and intermediately resis-
tant moxiﬂ   oxacin (MIC = 6 mg/L), 
whereas CD196, LUMC46, and A422 
were susceptible to both drugs.
The  slpA genes of all strains 
were ampliﬁ   ed by PCR mapping. 
Nine primers were designed on the 
slpA region to obtain 10 overlapping 
PCR products. The positions of the 
primers on the reference sequence 
FN545816 were 3161991–31612012,
3162346–3162365, 3162728–3162746, 
3162746–3162728, 3163514–3163495, 
3164222–3164205, 3163264–3163284, 
3163284–3163264, and 3164518–
3164499. Target ampliﬁ  cation  was 
performed by an initial denaturation 
at 94°C for 5 min, then 30 cycles of 
94°C for 1 min, 50°C for 1 min, and 
72°C for 1 min. Sequence assembly 
was performed by using DNAStar La-
sergene version 8.0 software (DNA-
Star, Madison, WI, USA). The protein 
analysis was performed by using the 
SignalP 3.0 server (www.cbs.dtu.dk/
services/SignalP/) and the ExPASy 
Proteomics server (www.expasy.ch/
tools/pi_tool.html). Amino acid com-
parisons were accomplished by using 
ClustalW (www.ebi.ac.uk/clustalw), 
and the output was used for construc-
tion of the phylogenetic tree by Tree-
View version 1.6.6 (http://en.bio-soft.
net/tree/TreeView.html). All PCR-
ribotype 027 strains showed the same 
slpA gene nucleotide sequence. The 
slpA precursor encoded by this gene 
contained a signal peptide, and its 
cleavage site was located between 
aa 24 and aa 25. The cleavage of the 
slpA precursor into LMW and HMW 
proteins was predicted between aa 
342 and aa 343 (N terminal to an Ala 
amino acid residue and C-terminal to 
a consensus motif Thr-Lys-Ser). The 
molecular masses of the LMW and 
HMW proteins were 33.871 kDa and 
44.174 kDa, respectively. These pro-
tein sizes were conﬁ  rmed by sodium 
dodecyl sulfate polyacrylamide gel 
electrophoresis, after a low pH gly-
cine extraction (data not shown). The 
phylogenetic tree (Figure), obtained 
by comparison with the amino acid 
sequences of other PCR ribotypes 
(6), showed that C. difﬁ  cile strain 027 
slpA was strongly related (identity 
89%) to that of strains belonging to 
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Figure. Phylogenetic tree based on the alignment of the surface layer protein A amino 
acid sequence of Clostridium difﬁ  cile 027 (GenBank accession no. CBE06198) with those 
of PCR-ribotypes 001, 002, 005, 010, 012, 014, 017, 031, 046, 054, 066, 078, 092, and 
094 (GenBank accession nos. AAZ05957, AAZ05964, AAZ05968, AAZ05974, AAZ05975, 
AAZ05984, AAZ05988, AAZ05989, AAZ05980, AAZ05972, AAZ05986, AAZ05994, 
AAZ05982, and AAZ05991, respectively). The phylogram was generated by using 
TreeView version 1.6.6 (http://en.bio-soft.net/tree/TreeView.html). The branch lengths are 
scaled in proportion to the extent of the change per position, as indicated by the scale bar.LETTERS
the epidemic PCR-ribotype 001. In 
particular, the identity between the 
2 PCR ribotypes was 100% for the 
HMW proteins and 77% for the LMW 
proteins.
This study provides convincing 
evidence that the S-layer is well con-
served in C. difﬁ  cile PCR-ribotype 
027 strains and has high identity with 
the slpA of the epidemic PCR-ribo-
type 001. Because C. difﬁ  cile PCR-
ribotypes 027 and 001 are the most 
frequently isolated strains from severe 
CDIs across both North America and 
Europe (9,10), the result obtained sug-
gests that the S-layer of these virulent 
strains presents peculiar and common 
characteristics that could be an advan-
tage for these bacteria during the in-
fection process.
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Introduction 
of Japanese 
Encephalitis Virus 
Genotype I, India 
To the Editor: Seasonal out-
breaks of fatal acute encephalitis syn-
drome (AES) occur regularly in sever-
al parts of India. Japanese encephalitis 
virus (JEV) has been the major and 
consistent cause of these outbreaks in 
the Gorakhpur region of Uttar Pradesh 
State, accounting for ≈10%–15% of 
total AES cases annually (1–3). In 
India, vaccinations against Japanese 
encephalitis (JE) are administered in 
areas where the disease is hyperen-
demic, including Gorakhpur, and AES 
cases are regularly investigated to 
clarify the effects of vaccination. Cur-
rently, >2,000 patients with AES are 
admitted each year to Baba Raghav 
Das Medical College, Gorakhpur.
JEV is classiﬁ  ed into 5 genotypes. 
Genotype III (GIII) is widely distrib-
uted in Asian countries, including 
Japan, South Korea, the People’s Re-
public of China, Taiwan, Vietnam, the 
Philippines, India, Nepal, and Sri Lan-
ka (4). However, during the past de-
cade, JEV GI has been introduced into 
South Korea, Thailand, and China and 
has replaced the GIII strains that had 
been circulating in Japan and Vietnam 
during the mid-1990s (5). Until 2007, 
all known JEV strains isolated in India 
belonged to GIII (2–4,6).
The JE-endemic Gorakhpur region 
recorded a sudden increase in AES cas-
es during September–November 2009. 
Clinical specimens collected from 694 
hospitalized patients were examined for 
JEV infection by JEV-speciﬁ  c immuno-
globulin M capture ELISA (7). Clinical 
specimens comprising 115 (16.6%) ce-
rebrospinal ﬂ  uid (CSF) specimens and 
114 (16.4%) serum specimens showed 
recent JE infection among 158 (22.7%) 
of the case-patients.
All CSF specimens were pro-
cessed for JEV genome detection by 
diagnostic reverse transcription–PCR 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011  319 